Overview
Daniel Berinstein is an Ophthalmologist in Chevy Chase, Maryland. Dr. Berinstein is rated as an Experienced provider by MediFind in the treatment of Retinitis Pigmentosa. His top areas of expertise are Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Retinal Detachment, Retinal Vein Occlusion, and Vitrectomy. Dr. Berinstein is currently accepting new patients.
His clinical research consists of co-authoring 7 peer reviewed articles. MediFind looks at clinical research from the past 15 years.
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- EPO
- HMO
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- EPO
- POS
- PPO
- HMO
- OTHER MANAGED MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
5454 Wisconsin Ave, Suite 650, Chevy Chase, MD 20815
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
The Johns Hopkins Hospital
Peter A. Campochiaro, M.D. is the George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins University School of Medicine. He is a clinician-scientist who directs a research laboratory and conducts clinical trials. His laboratory research is directed at understanding the pathogenesis of ocular neovascularization and excessive retinal vascular permeability, and the mechanism of cone cell death in inherited retinal degenerations. He helped to determine the importance of vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1, and Tie2 in retinal and choroidal vascular diseases. The clinical trial group under Dr. Campochairo provided the first demonstration of the benefits of suppression of VEGF in diabetic macular edema and retinal vein occlusion. He has developed strategies for sustained suppression of VEGF that are currently being tested in clinical trials. Dr. Campochiaro trained at the University of Notre Dame, Johns Hopkins School of Medicine, and the University of Virginia. He did a vitreoretinal fellowship and research fellowships at Johns Hopkins and joined the faculty of the University of Virginia in 1984. He became professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins in 1991. Dr. Campochiaro is rated as an Elite provider by MediFind in the treatment of Retinitis Pigmentosa. His top areas of expertise are Retinal Vein Occlusion, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Trabeculectomy, and Vitrectomy.
The Johns Hopkins Hospital
Mandeep S. Singh, M.D., Ph.D., is associate professor of ophthalmology and genetic medicine in the Retina Division of the Wilmer Eye Institute and the recipient of the 2023 Andreas C. Dracopoulos Professorship in Ophthalmology. Dr. Singh is a retinal specialist. He is Co-Director of the Genetic Eye Disease (GEDi) Center, and is a principal investigator at the Center for Stem Cells and Ocular Regenerative Medicine (STORM). Dr. Singh completed his medical degree at the National University of Singapore. In 2009, he was elected to the Fellow of the Royal College of Surgeons of Edinburgh. He earned a PhD in ophthalmology from the University of Oxford, United Kingdom, in 2014. He completed fellowships in vitreoretinal diseases and surgery at the Oxford Eye Hospital and Moorfields Eye Hospital, both in the United Kingdom. His clinical expertise includes surgical, medical and genetic conditions of the retina and macula. Dr. Singh is specialty-trained in vitrectomy surgery for retinal detachment, macular holes, macular pucker, epiretinal membrane, proliferative vitreoretinopathy, complex retinal detachments including reoperations, vitreous hemorrhage removal, and other retinal surgeries. He also specializes in age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vein occlusion, and choroidal neovascularization. Dr. Singh sees patients and families with genetic retinal diseases such as retinitis pigmentosa, Usher syndrome, Stargardt disease and macular dystrophies. His research focus is retinal stem cell transplantation. Dr. Singh’s work has been recognized through the Eye Institute–Allergan Research Prize, the Merton College University of Oxford Graduate Prize Scholarship, the Oxford Ophthalmological Congress Founder’s Cup and Medal, the Ruskell Medal, the Johns Hopkins Clinician Scientist Award, and the Bert M. Glaser, MD Award for Innovative Research in Retina. He is a member of the American Academy of Ophthalmology and the Association for Research in Vision and Ophthalmology. He is also a member of the Club Jules Gonin and the Macula Society. CV https://www.hopkinsmedicine.org/-/media/wilmer/documents/cvs/Singh_CV.pdf. Dr. Singh is rated as a Distinguished provider by MediFind in the treatment of Retinitis Pigmentosa. His top areas of expertise are Leber Congenital Amaurosis, Sorsby Fundus Dystrophy, Usher Syndrome Type 2A, and Doyne Honeycomb Retinal Dystrophy.
Catherine Cukras is an Ophthalmologist in Bethesda, Maryland. Dr. Cukras is rated as an Elite provider by MediFind in the treatment of Retinitis Pigmentosa. Her top areas of expertise are Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Geographic Atrophy, and Retinopathy Pigmentary Mental Retardation.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Age-Related Macular Degeneration (ARMD)Dr. Berinstein isDistinguished. Learn about Age-Related Macular Degeneration (ARMD).
- Late-Onset Retinal DegenerationDr. Berinstein isDistinguished. Learn about Late-Onset Retinal Degeneration.
- Retinal DetachmentDr. Berinstein isDistinguished. Learn about Retinal Detachment.
- Advanced
- Choroid Plexus CarcinomaDr. Berinstein isAdvanced. Learn about Choroid Plexus Carcinoma.
- Diabetic RetinopathyDr. Berinstein isAdvanced. Learn about Diabetic Retinopathy.
- EndophthalmitisDr. Berinstein isAdvanced. Learn about Endophthalmitis.
- NearsightednessDr. Berinstein isAdvanced. Learn about Nearsightedness.
- NeuroretinitisDr. Berinstein isAdvanced. Learn about Neuroretinitis.
- Retinal Artery OcclusionDr. Berinstein isAdvanced. Learn about Retinal Artery Occlusion.
- Experienced
- Autosomal Dominant VitreoretinochoroidopathyDr. Berinstein isExperienced. Learn about Autosomal Dominant Vitreoretinochoroidopathy.
- CataractDr. Berinstein isExperienced. Learn about Cataract.
- Central Serous ChorioretinopathyDr. Berinstein isExperienced. Learn about Central Serous Chorioretinopathy.
- Cone DystrophyDr. Berinstein isExperienced. Learn about Cone Dystrophy.
- Cone Rod Dystrophy Amelogenesis ImperfectaDr. Berinstein isExperienced. Learn about Cone Rod Dystrophy Amelogenesis Imperfecta.
- Cone-Rod DystrophyDr. Berinstein isExperienced. Learn about Cone-Rod Dystrophy.

